TKNO earnings analysis
What we found in TKNO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Alpha Teknova, Inc. reported Q1 2026 revenue of $11.1 million, a year-over-year increase of 13% and beating consensus estimates. The gross margin improved to 34.2%, and the company reported an EPS loss of $-0.08, exceeding the expected loss of $-0.09. Despite ongoing operational challenges, management emphasized growth in the Clinical Solutions segment and reiterated their revenue guidance for the year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeded Estimates
- Reported revenue of $11.1 million surpassed expectations of $10.1 million, marking a 13.1% increase YoY.
- Improved Gross Margin
- Gross margin increased to 34.2%, up from 30.7% in the prior year.
- Clinical Solutions Segment Growth
- Clinical Solutions revenue grew by 84.6%, reaching $2.1 million compared to $1.2 million YoY.
- Lower Operating Loss
- Operating loss narrowed to $4.3 million, compared to $5.0 million a year ago.
- Cash and Working Capital Position
- As of March 31, 2026, cash and cash equivalents totaled $17.8 million.
- Reaffirmed 2026 Revenue Guidance
- Management reiterated the revenue guidance of $42-$44 million for full-year 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Net Losses
- Net loss for Q1 2026 was $4.6 million, slightly improved from $4.7 million last year.
- Increasing Operating Expenses
- Total operating expenses rose 1.4% year-over-year, placing strain on profitability.
- Dependence on External Suppliers
- Relying on limited suppliers for raw materials could disrupt production if issues arise.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.08
- Gross margin
- 34.2%
- Segment
- Lab Essentials: $8.4 million
- Segment
- Clinical Solutions: $2.1 million
What they said about what is next.
Management reaffirmed the anticipated revenue range for 2026 between $42 and $44 million.
The filing reads better than the one before it.
What came before.
- 10-K · March 2, 2026
- Teknova delivered revenue growth in 2025 with Q4 revenue of $10.0M and full-year results described as up 7% to $40.5M, while continuing to operate at a loss. The company emphasizes a differentiated, fast-to-customize…
- 10-Q · November 13, 2023
- Alpha Teknova reported Q3 revenue of $8.169M (down from $10.692M a year ago) and a GAAP net loss of $10.153M (-$0.34 per share). Management raised equity ($22.915M gross) and repaid $10.0M of term debt, but the MD&A…
- 10-K · March 30, 2023
- Teknova positions itself as a custom, fast-turnaround manufacturer of critical life-science reagents with proprietary processes and ISO/GMP capabilities, serving more than 3,000 active customers. The 10-K emphasizes…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TKNO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever